TECHNETIUM TC 99M MPI MDP
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M MPI MDP (TECHNETIUM TC 99M MPI MDP).
Technetium Tc-99m medronate (MDP) is a radiopharmaceutical that localizes in bone via chemisorption onto hydroxyapatite crystals, particularly in areas of increased osteoblastic activity. The Tc-99m label emits gamma rays detectable by gamma cameras, allowing imaging of skeletal abnormalities.
| Metabolism | Not metabolized; it undergoes renal elimination as the intact complex via glomerular filtration. |
| Excretion | Renal: ~70% eliminated unchanged in urine within 24 hours; biliary/fecal: minimal (<5%) |
| Half-life | Terminal elimination half-life: 6 hours (range 4-8). Clinical context: allows imaging up to 4 hours post-injection; accumulation in bone lesions peaks at 2-4 hours. |
| Protein binding | ~25% bound to serum albumin and globulins |
| Volume of Distribution | 0.2-0.4 L/kg; reflects distribution into extracellular fluid and bone |
| Bioavailability | IV: 100% bioavailability (only IV route used) |
| Onset of Action | IV: Bone uptake detectable by 30 minutes, peak bone-to-soft tissue ratio at 2-4 hours |
| Duration of Action | Duration of clinically useful imaging: 2-4 hours post-injection; agent cleared from soft tissue by 4 hours with persistent bone uptake for 6-12 hours |
15-30 mCi (555-1110 MBq) intravenously, single dose, followed by imaging 2-3 hours post-injection.
| Dosage form | INJECTABLE |
| Renal impairment | No specific dose adjustment. Use with caution in severe renal impairment; consider delayed imaging due to reduced clearance. |
| Liver impairment | No adjustment necessary based on hepatic function. |
| Pediatric use | Weight-based: 0.2-0.3 mCi/kg (7.4-11.1 MBq/kg) intravenously, minimum 1 mCi (37 MBq). |
| Geriatric use | No specific dose adjustment; standard adult dose may be used. Ensure adequate hydration and frequent voiding. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNETIUM TC 99M MPI MDP (TECHNETIUM TC 99M MPI MDP).
| Breastfeeding | Breastfeeding should be interrupted for a period determined by the half-life (6 hours) and specific radioactivity clearance. Typically, pump and discard milk for 24-48 hours post-injection. M/P ratio not established; radioactivity can transfer to milk. Consult institutional radiation safety guidelines. |
| Teratogenic Risk | Technetium Tc-99m is a radioactive isotope. Fetal radiation exposure depends on maternal dose and gestational stage. First trimester: highest risk for teratogenesis (malformations, growth restriction, neurodevelopmental effects); use only if essential and benefit outweighs risk. Second and third trimesters: lower risk but still potential for stochastic effects (carcinogenesis); minimize radiation dose. No known non-radiation teratogenicity. |
■ FDA Black Box Warning
None
| Serious Effects |
["Absolute: Hypersensitivity to any component (rare).","Relative: Pregnancy (unless benefit outweighs risk), lactation (discontinue nursing for 24 hours), inability to hydrate or void."]
| Precautions | ["Risk of radiation exposure; use only if diagnostic benefit outweighs risk.","Hydrate patient before and after injection to reduce radiation dose to bladder.","Pregnancy category D; avoid in pregnant women unless essential.","Ensure patient voids frequently after administration to minimize bladder radiation.","Allergic reactions (rare) may occur."] |
Loading safety data…
| Fetal Monitoring | No specific monitoring beyond standard for radiopharmaceutical administration. Ensure maternal hydration to enhance renal clearance; monitor for injection site reactions. Fetal radiation dose should be calculated; consider alternative imaging if pregnant (e.g., MRI). Use lowest effective dose. |
| Fertility Effects | Technetium Tc-99m decays via isomeric transition, emitting gamma rays; no direct evidence of adverse effects on fertility. Theoretical risk to gonads from radiation exposure; cumulative radiation dose should be minimized. No human studies on fertility impairment. |